Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.51 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.45 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.45 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423798 | 0.87 | MAP2K1 (0.46) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL12423806 | 0.83 | MAP2K1 (0.45) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL2294850 | 0.82 | MAP2K1 (0.49) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL12423799 | 0.80 | MAP2K1 (0.51) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL16103816 | 0.78 | MAP2K1 (0.53) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL3265187 | 0.77 | MAP2K1 (0.55) | MAP2K1MAP2K2METAP2FLT1 | |
| SCHEMBL3265182 | 0.77 | MAP2K1 (0.61) | MAP2K1MAP2K2 | |
| SCHEMBL13522225 | 0.76 | MAP2K1 (0.52) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL1578880 | 0.75 | MAP2K1 (0.51) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL12423782 | 0.71 | MAP2K1 (0.57) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | disclosed |
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003025-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENENTECH, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | MAP2K7, MAP3K1, MAP3K5 | MAP2K1 11/4885MAP2K2 4/4885CHEK1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.